Yearly Archives: 2017

First ARM2 patient included

on 17/11/2017 Allgemein with 0 comments

The study ARM2 of the TNBC-MERIT clinical trial was opened in September 2017 by recommendation of the DSMB. The first patient was enrolled in October 2017 in Germany. The patient will receive the on-demand manufactured individualized cancer vaccine at the beginning of next year.

Read more

MERIT at CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference

on 17/11/2017 Allgemein with 0 comments

The MERIT Project was successfully presented to the scientific community at the Third CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference in Mainz, Germany on September 6-9, 2017.

Read more

MERIT Annual Meeting 2017

on 25/04/2017 Allgemein with 0 comments

The consortium partners of the MERIT project came together in Uppsala, Sweden on September 12th to discuss the project status, preliminary data from the first patients and scientific advances that have been achieved within the last year. The meeting was kindly hosted by Consortium Partner Tobias Sjöblom from Uppsala University.

Read more